📰 Interim Analysis News
Page 4 - Interim Analysis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Interim Analysis. Real-time updates on events, politics, business and more.
April 24, 2023
– Pivotal Phase III data will be spotlighted via an oral presentation – – Additional efficacy and safety data will be featured across four posters – ... | June 18, 2023
April 21, 2023
In several abstracts presented at this year's American Academy of Neurology Annual Meeting, Mitzi Joi Williams, MD, FAAN, Joi Life Wellness Neurology Clinic, explores multiple sclerosis–related outcomes in diverse patient populations.
April 11, 2023
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® tablets The U.S. Food and Drug Administration ... | April 11, 2023
March 13, 2023
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American...
January 19, 2023
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate
December 16, 2022
Investegate announcements from Oxford BioDynamics, Initial assessment of EpiSwitch assay in ALS trial
December 11, 2022
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia
December 11, 2022
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or...
December 11, 2022
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia A without... | December 11, 2022
December 11, 2022
Investegate announcements from F. Hoffmann-La Roche Ltd, Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth